Christopher Starr
Founder bij MONOPAR THERAPEUTICS INC.
Vermogen: 51 254 $ op 31-03-2024
Profiel
Christopher M.
Starr was the founder of BioMarin Pharmaceutical, Inc. (founded in 1997) where he held the title of Chief Scientific Officer & Senior Vice President in 2006.
He was also the founder of Raptor Pharmaceuticals Corp.
(founded in 2006) where he served as President, Chief Executive Officer & Director from 2006 to 2014.
Additionally, he founded Horizon Pharmaceutical LLC (founded in 2009) and held the position of Independent Director from 2015 to 2016.
In 2014, Dr. Starr founded Monopar Therapeutics, Inc. and currently serves as the Executive Chairman.
His current jobs include being the Chief Executive Officer of Raptor Discoveries, Inc. since 2005, Chairman of Thiogenesis Therapeutics, Inc., Chairman of Thiogenesis Therapeutics Corp.
since 2022, and Director of Glycomine, Inc. since 2016.
Dr. Starr's former jobs include being the Vice President-Research & Development at Glyko, Inc. from 1991 to 1998 and an Associate at The National Research Council.
He obtained a doctorate degree from SUNY Upstate Medical University and an undergraduate degree from Syracuse University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
MONOPAR THERAPEUTICS INC
0.51% | 08-03-2024 | 75 263 ( 0.51% ) | 51 254 $ | 31-03-2024 |
| 08-12-2022 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Christopher Starr
| Bedrijven | Functie | Begin |
|---|---|---|
| MONOPAR THERAPEUTICS INC. | Founder | 01-12-2014 |
| THIOGENESIS THERAPEUTICS, CORP. | Chairman | 31-03-2022 |
| Raptor Discoveries, Inc. | Chief Executive Officer | 08-09-2005 |
Glycomine, Inc.
 Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Director/Board Member | - |
Eerdere bekende functies van Christopher Starr
| Bedrijven | Functie | Einde |
|---|---|---|
| RAPTOR PHARMACEUTICAL CORP | Founder | 25-10-2016 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Founder | 01-12-2014 |
| BIOMARIN PHARMACEUTICAL INC. | Founder | 01-01-2006 |
Glyko, Inc.
 Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The private company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Chief Tech/Sci/R&D Officer | 01-01-1998 |
The National Research Council
 The National Research Council Miscellaneous Commercial ServicesCommercial Services The National Research Council provides science, technology and health policy consulting and advice. The company was founded in 1916 and is headquartered in Washington, DC. | Corporate Officer/Principal | - |
Opleiding van Christopher Starr
| SUNY Upstate Medical University | Doctorate Degree |
| Syracuse University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Bedrijven in privébezit | 8 |
|---|---|
Glyko, Inc.
Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The private company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Health Technology |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
The National Research Council
The National Research Council Miscellaneous Commercial ServicesCommercial Services The National Research Council provides science, technology and health policy consulting and advice. The company was founded in 1916 and is headquartered in Washington, DC. | Commercial Services |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
| Raptor Discoveries, Inc. | |
| Monopar Therapeutics, Inc. | |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Health Technology |
| Thiogenesis Therapeutics Corp. |
